Biotech Industry News

A collection of Biotech latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.

cnbc.com - Lisa Kailai Han - A biotech stock for investors scared to invest in the risky industry
A biotech stock for investors scared to invest in the risky industry
CNBC

Citigroup thinks investors should consider Ligand Pharmaceuticals for a more conservative bet on the biotech industry. The bank initiated the biotech stock at a buy rating and price target of $270, implying upside of 46% from Ligand's Monday…

globenewswire.com - Idorsia Pharmaceuticals Ltd - Idorsia's treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the 'Best Biotechnology & Pharmaceutical Product' category
Idorsia's treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the 'Best Biotechnology & Pharmaceutical Product' category
GlobeNewswire

Idorsia's dual orexin receptor antagonist, the first and only drug of its kind approved in Europe for the treatment of insomnia disorder, has been awarded the inaugural Prix Galien Bridges Award in the category of “Best Biotechnology &…

cnbc.com - Lisa Kailai Han - A little-known biotech stock more than doubled this week. Why Wells Fargo sees further upside
A little-known biotech stock more than doubled this week. Why Wells Fargo sees further upside
CNBC

Wave Life Sciences offers an exciting new obesity treatment that can translate to big gains ahead, according to Wells Fargo. The bank reiterated the Singapore-based biotech name as overweight and hiked its price target to $29 per share from $16.

koreaherald.com - Choi Jeong-yoon - Seoul attracts $50m biotech investment from China's venture capital
Seoul attracts $50m biotech investment from China's venture capital
The Korea Herald

Seoul has secured a $50 million investment commitment through a memorandum of understanding with a major Chinese health care venture capital firm, as the city moves to deepen cross-border cooperation in finance, biotechnology and robotics…

rollingout.com - Tega Egwabor - Biotech stock soars 40% on JPMorgan's bold call
Biotech stock soars 40% on JPMorgan's bold call
Rolling Out

JPMorgan's bullish rating sends Vor Biopharma shares skyrocketing on promising autoimmune disease treatment Vor Biopharma experienced a remarkable morning on December 9, 2025, as shares of the biotech company surged more than 40% in premarket…

cityam.com - Business Wire - ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive
ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive
City AM

ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey, while the second survey focused…

boston.com - Abby Patkin - Average Boston rent down for first time in years - but still over $3K
Average Boston rent down for first time in years - but still over $3K
Boston.com

Boston's rental market has tipped ever-so-slightly in renters' favor, partially owing to out-of-state migration, a cooling biotech industry, and tighter student visa restrictions, according to a recent Bloomberg report. On the one hand, vacancies…

marketbeat.com - Promising Biotech Stocks To Keep An Eye On - December 9th
Promising Biotech Stocks To Keep An Eye On - December 9th
MarketBeat

Wave Life Sciences Rockets 70% on Historic RNA Editing Success WAVE Life Sciences, Exicure, argenex, Danaher, Senti Biosciences, Abivax, and Vertex Pharmaceuticals are the seven Biotech stocks to watch today, according to MarketBeat's stock…

marketbeat.com - Legend Biotech (NASDAQ:LEGN) Trading Down 4.7% - Time to Sell?
Legend Biotech (NASDAQ:LEGN) Trading Down 4.7% - Time to Sell?
MarketBeat

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN - Get Free Report) shares were down 4.7% during mid-day trading on Tuesday. The company traded as low as $24.22 and last traded at $24.8970. Approximately 1,571,366 shares were traded during…

seekingalpha.com - Petri Dish Reports - Mounjaro In China: Assessing Market Potential And Risks (NYSE:LLY)
Mounjaro In China: Assessing Market Potential And Risks (NYSE:LLY)
Seeking Alpha

Eli Lilly (LLY) is set to add Mounjaro to China's national reimbursement list, dramatically expanding its reach in the diabetes market. LLY's bull case hinges on securing reimbursement for Mounjaro's obesity and sleep apnea indications, unlocking…

ethz.ch - A Trojan horse for artificial amino acids
A Trojan horse for artificial amino acids
ETH Zürich

Researchers from ETH Zurich have modified a bacterial transport system so that it can efficiently introduce large quantities of unnatural amino acids into cells, disguised as a kind of Trojan horse. All organisms manufacture their proteins from the…

thestar.com.my - Justice - Ghanaian president urges private sector to co-invest in Africa's health industrialization
Ghanaian president urges private sector to co-invest in Africa's health industrialization
The Star Online

ACCRA, Dec. 9 (Xinhua) -- Ghanaian President John Dramani Mahama on Tuesday urged private sector players to collaborate with African governments in co-investing in the continent's health industrialization to enhance healthcare and service delivery.

thehill.com - Julia Shapero - Here are key tech provisions the NDAA includes and excludes
Here are key tech provisions the NDAA includes and excludes
The Hill

Two key AI provisions were left out of the final text of the National Defense Authorization Act (NDAA) after failing to overcome Republican divisions, while a pair of measures restricting investments and contracts with China made it into the…

bloomberg.com - Juliana Liu - Big Pharma's Patent Cliff Puts China Front and Center
Big Pharma's Patent Cliff Puts China Front and Center
Bloomberg

For pharmaceutical firms, watching the lucrative patents on their top-selling drugs expire has long been part of the business cycle. There's enormous pressure to find ways of covering the shortfall. For the first time, China has something to offer.

newswire.ca - Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival
Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival
CNW

LAS VEGAS, Dec. 9, 2025 /CNW/ -- Avant Technologies, Inc. (OTCQB: AVAI) ('Avant' or the 'Company'), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced a newly…

Receive a Daily briefing on Biotech Industry News

Get Started